ANAVEX2-73 Study in Parkinson's Disease Dementia

Parkinsons Disease With Dementia Clinical Trial

Official title:
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients With Parkinson's Disease With Dementia

Status Completed

Clinical Trial Summary

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)

Clinical Trial Description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration Period), and a 2-week Safety Follow-Up Period ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03774459
Study type	Interventional
Source	Anavex Life Sciences Corp.
Contact
Status	Completed
Phase	Phase 2
Start date	July 9, 2018
Completion date	September 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04335994` - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing	N/A
Active, not recruiting	`NCT03608553` - A Study to Evaluate Temporary Blood Brain Barrier Disruption in Patients With Parkinson's Disease Dementia	N/A
Recruiting	`NCT04148326` - A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
Recruiting	`NCT04389437` - OCT-Angiography and Adaptive Optics in Patients With Memory Impairment	N/A
Active, not recruiting	`NCT02954978` - Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease	Phase 2
Completed	`NCT00988117` - The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems	Phase 4